Cat. No. | Product name | CAS No. |
DC5032 |
AZD1480
Featured
AZD1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. Phase 1/2. |
935666-88-9 |
DC10724 |
AZD2098
Featured
AZD2098 is a potent CC-chemokine receptor 4 (CCR4) inhibitor, used for asthma research. |
566203-88-1 |
DC9946 |
Lanabecestat(AZD3293,LY-3314814)
AZD3293 is a potent and selective orally active, brain-permeable BACE1 inhibitor,currently in development as a potential treatment for early Alzheimer’s disease. |
1383982-64-6 |
DC8472 |
AZD-3759
Featured
AZD3759 is an orally available inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. |
1626387-80-1 |
DC8400 |
AZD3839
Featured
AZD3839 is a potent and selective BACE1 inhibitor with Ki of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1. |
1227163-84-9 |
DC9263 |
AZD-3965
Featured
AZD3965 is a selective inhibitor of monocarboxylate transporter 1 (MCT1) with a binding affinity of 1.6 nM, is 6 fold selective over MCT2 and does not inhibit MCT4 at 10 μM. |
1448671-31-5 |
DC1075 |
AZD4547
Featured
AZD4547 is a novel selective FGFR inhibitor targeting FGFR1, FGFR2, and FGFR3 with IC50 of of 0.2 nM, 2.5 nM, and 1.8 nM, respectively. |
1035270-39-3 |
DC11295 |
AZD-4573
AZD4573 is a CDK9 inhibitor with an IC50 of <3 nM extracted from patent US 20160376287 A1, example 14. |
2057509-72-3 |
DC10739 |
AZD4635
Featured
AZD4635 is a novel adenosine 2A receptor (A2AR) inhibitor with a Ki of 1.7 nM. |
1321514-06-0 |
DC10773 |
AZD5069
Featured
AZD-5069 is a potent and selective CXCR2 antagonist with the potential to inhibit neutrophil migration into the airways in patients with COPD. |
878385-84-3 |
DC10774 |
AZD5153
Featured
AZD5153 is a potent bivalent triazolopyridazine based Bromodomain and Extraterminal (BET) Inhibitor. |
1869912-39-9 |
DC7369 |
AZD5438
Featured
AZD5438 is a potent inhibitor of CDK1/2/9 with IC50 of 16 nM/6 nM/20 nM. It is less potent to CDK5/6. |
602306-29-6 |
DC1069 |
AZD6244 (Selumetinib,ARRY-142886)
Featured
AZD6244 (Selumetinib, ARRY-142886) is highly potent to inhibit MEK1 with IC50 of 14 nM. |
606143-52-6 |
DC8004 |
AZD6482
Featured
AZD6482 is a PI3Kβ inhibitor with IC50 of 10 nM, 8-, 87- and 109-fold more selective to PI3Kβ than PI3Kδ, PI3Kα and PI3Kγ. |
1173900-33-8 |
DC8468 |
AZD-6738
Featured
AZD6738 is an orally active, and selective ATR kinase inhibitor with IC50 of 1 nM. Phase 1/2. |
1352226-88-0 |
DC7076 |
AZD-7762
Featured
AZD7762 is a potent and selective inhibitor of Chk1 with IC50 of 5 nM; equally potent against Chk2 and less potent against CAM, Yes, Fyn, Lyn, Hck and Lck. |
860352-01-8 |
DC11723 |
AZD-7986(Brensocatib)
Featured
AZD-7986(Brensocatib) is a highly potent, reversible, and selective DPP1 inhibitor with enzyme and cell pIC50 of 8.4. |
1802148-05-5 |
DC5084 |
AZD-8055
Featured
AZD-8055 is a potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM. |
1009298-09-2 |
DC8380 |
AZD8186
Featured
AZD8186 is an inhibitor of the beta isoform of phosphoinositide-3 kinase (PI3K), with potential antineoplastic activity. |
1627494-13-6 |
DC7077 |
AZD8330(ARRY-424704; ARRY-704)
Featured
AZD8330(ARRY-424704; ARRY-704) is a novel, selective, non-ATP competitive MEK 1/2 inhibitor with IC50 of 7 nM. |
869357-68-6 |
DC9879 |
AZD8835
Featured
AZD8835 ia a novel mixed inhibitor of PI3Kα and PI3Kδ with IC50 of 6.2 nM and 5.7 nM, respectively, also with selectivity against PI3Kβ (IC50=431 nM) and PI3Kγ (IC50=90 nM). |
1620576-64-8 |
DC10425 |
AZD9056 hydrochloride
AZD9056 is a selective orally active inhibitor of P2X7 which plays a significant role in inflammation and pain-causing diseases. |
345303-91-5 |